Eddie Hickman
Stock Analyst at Guggenheim
(3.49)
# 742
Out of 5,182 analysts
22
Total ratings
66.67%
Success rate
18.7%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eddie Hickman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ATAI AtaiBeckley | Maintains: Buy | $11 → $16 | $4.63 | +245.57% | 2 | Apr 17, 2026 | |
| TARS Tarsus Pharmaceuticals | Maintains: Buy | $87 → $90 | $61.45 | +46.46% | 10 | Feb 25, 2026 | |
| PMN ProMIS Neurosciences | Maintains: Buy | $125 → $35 | $11.24 | +211.39% | 4 | Feb 6, 2026 | |
| OTLK Outlook Therapeutics | Downgrades: Neutral | n/a | $0.32 | - | 4 | Aug 29, 2025 | |
| ZVRA Zevra Therapeutics | Maintains: Buy | $20 → $22 | $10.08 | +118.25% | 1 | Mar 13, 2025 | |
| GHRS GH Research | Initiates: Buy | $32 | $20.25 | +58.02% | 1 | Mar 13, 2025 |
AtaiBeckley
Apr 17, 2026
Maintains: Buy
Price Target: $11 → $16
Current: $4.63
Upside: +245.57%
Tarsus Pharmaceuticals
Feb 25, 2026
Maintains: Buy
Price Target: $87 → $90
Current: $61.45
Upside: +46.46%
ProMIS Neurosciences
Feb 6, 2026
Maintains: Buy
Price Target: $125 → $35
Current: $11.24
Upside: +211.39%
Outlook Therapeutics
Aug 29, 2025
Downgrades: Neutral
Price Target: n/a
Current: $0.32
Upside: -
Zevra Therapeutics
Mar 13, 2025
Maintains: Buy
Price Target: $20 → $22
Current: $10.08
Upside: +118.25%
GH Research
Mar 13, 2025
Initiates: Buy
Price Target: $32
Current: $20.25
Upside: +58.02%